Split course radiation therapy for adenocarcinoma of the pancreas.
Ninety-five patients with biopsy proven adenocarcinoma of the pancreas were treated with split course radiation therapy. Fifty-five patients had disease confined to the peripancreatic tissues and lymph nodes. Forty patients had metastatic disease. The intended radiation therapy scheduled consisted of two courses of 25 Gy in 10 fractions each followed by a 3 to 4 week rest period. Depending on the response and the patient's clinical status, another 10 Gy in 5 fractions was administered as a final boost. The median survival in patients with metastatic disease was 3 months and the median survival in patients with localized disease was 8 months. Twenty-seven of the fifty-five patients with localized disease received chemotherapy (5 FU or FAM) combined with radiotherapy. There was no significant difference in median survival between the patients treated with radiation alone and those with combined radiation and chemotherapy. The median survival for patients with localized disease receiving 25, 50, and 60 Gy were 3, 7, and 12 months respectively. After a dose of 50 Gy in 20 fractions, CT scan showed no evidence of tumor in 6%, smaller tumor size in 31%, stable tumor size in 41%, and tumor growth in 22% of patients. The split course radiation therapy was well tolerated and no late complications were detected. The medical and economic advantages of using split course radiation therapy and in using CT scan response to plan boost therapy are discussed.
Flickinger
J C
JC
Joint Radiation Oncology Center, University of Pittsburgh, PA 15213.
Jawalekar
K
K
Deutsch
M
M
Webster
J
J
D000230:Adenocarcinoma / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D008297:Male; D010166:Palliative Care; D010190:Pancreatic Neoplasms / Q000532:radiotherapy*; D011379:Prognosis; D011879:Radiotherapy Dosage